���构特征与受体作用机制 — Quick Reference

By Editorial Desk · published 2026-06-02 · last reviewed 2026-07-15 · Faq

This is a working overview of lyophilisation, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-07-15 and is reviewed periodically as new material appears.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。

Storage, Stability, and Analytical Control

Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.

Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.

Semaglutide at a glance

Background and Molecular Design

Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.

The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.

Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.

Related pages on this site

• Seasonal archive
• Practical summary
• Modern workbook
• Focused analysis
• Verified casebook
• Clear analysis
• Proven summary
• Quality summary

Handling, Storage, and Quality Control

Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.

Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.

Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.

Handling, Storage, and Characterization

Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.

Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.

Handling, Storage, and Analysis

Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.

Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.

Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.

Supporting material

=== Infertility === It can be difficult to become pregnant with PMOS due to irregular ovulation. The first management step is to improve the general health of the mother, such as through lifestyle interventions. GLP-1 agonist for weight loss can be used, but should be stopped at least 2 months before conception. As of 2025, there is not enough data to know if they are safe in pregnancy. Pregnancy in PMOS is more risky than normal, and treatment is focused on getting a single pregnancy, rather than, for instance, twins (multiple pregnancy). With treatment, the eventual family size of women with PMOS does not seem different to those without. The first-line medical treatment for infertility in women with PMOS is letrozole (Femara) to induce ovulation. This is, in general, more effective than clomiphene citrate to improve both pregnancy rates and live births. Other medications that can be used to treat infertility, listed from most to least effective, are metformin + clomiphene citrate, clomiphene citrate alone, and metformin alone. Women may be more likely to experience gastrointestinal side effects with metformin. Gonadotrophin therapy may be effective too, but requires monitoring and increases the risks of multiple pregnancies. When medication and lifestyle interventions are ineffective, infertility can be treated with a laparoscopic procedure called "ovarian drilling", which involves puncture of 4–10 small follicles with electrocautery, laser, or biopsy needles.

== Medical uses == Recombinant human epidermal growth factor, sold under the brand name Heberprot-P, is used to treat diabetic foot ulcers. It can be given by injection into the wound site, or may be used topically. Tentative evidence shows improved wound healing. Safety has been poorly studied. EGF is used to modify synthetic scaffolds for manufacturing of bioengineered grafts by emulsion electrospinning or surface modification methods.

==== Testosterone ==== Libido in males is linked to concentrations of sex hormones, particularly testosterone. When there is reduced sex drive in individuals with relatively low concentrations of testosterone, particularly in postmenopausal women or men over the age of 60, dietary supplements that are purported to increase serum testosterone concentrations have been used, with the intention of increasing libido, although with limited benefits. Long-term therapy with synthetic oral testosterone is associated with increased risks of cardiovascular diseases.

Sources: en.wikipedia.org

Notes from published material

The body also absorbs less iron during times of inflammation, in order to deprive bacteria of iron. Recent discoveries demonstrate that hepcidin regulation of ferroportin is responsible for the syndrome of anemia of chronic disease.

The territorial organisation of the Republic of Serbia was regulated by the Law on Territorial Organisation and Local Self-Government, adopted in the Assembly of Serbia on 24 July 1991. Under the Law, the municipalities, cities and settlements make the bases of the territorial organization. Serbia was divided into 195 municipalities and 4 cities, which were the basic units of local autonomy. It had two autonomous provinces: Kosovo and Metohija in the south (with 30 municipalities), which was under the administration of UNMIK after 1999, and Vojvodina in the north (with 46 municipalities and 1 city). The territory between Kosovo and Vojvodina was called Central Serbia. Central Serbia was not an administrative division on its own and had no regional government of its own. In addition, there were four cities: Belgrade, Niš, Novi Sad and Kragujevac, each having an assembly and budget of its own. The cities comprised several municipalities, divided into "urban" (in the city proper) and "other" (suburban). Competences of cities and their municipalities were divided. Municipalities were gathered into districts, which are regional centres of state authority, but have no assemblies of their own; they present purely administrative divisions, and host various state institutions such as funds, office branches and courts. The Republic of Serbia was then and is still today divided into 29 districts (17 in Central Serbia, 7 in Vojvodina and 5 in Kosovo, which are now defunct), while the city of Belgrade presents a district of its own.

==== Heart failure ==== As well as addressing the underlying cause for a patient's heart failure (most commonly ischemic heart disease or hypertension), the mainstay of heart failure treatment is with medication. These include drugs to prevent fluid from accumulating in the lungs by increasing the amount of urine a patient produces (diuretics), and drugs that attempt to preserve the pumping function of the heart (beta blockers, ACE inhibitors and mineralocorticoid receptor antagonists). In some patients with heart failure, a specialised pacemaker known as cardiac resynchronisation therapy can be used to improve the heart's pumping efficiency. These devices are frequently combined with a defibrillator. In very severe cases of heart failure, a small pump called a ventricular assist device may be implanted which supplements the heart's own pumping ability. In the most severe cases, a cardiac transplant may be considered.

Stream power, originally derived by R. A. Bagnold in the 1960s, is the amount of energy the water in a river or stream is exerting on the sides and bottom of the river. Stream power is the result of multiplying the density of the water, the acceleration of the water due to gravity, the volume of water flowing through the river, and the slope of that water. There are many forms of the stream power formula with varying utilities, such as comparing rivers of various widths or quantifying the energy required to move sediment of a certain size. Stream power is closely related to other criteria such as stream competency and shear stress. Stream power is a valuable measurement for hydrologists and geomorphologists tackling sediment transport issues as well as for civil engineers, who use it in the planning and construction of roads, bridges, dams, and culverts.

Sources: en.wikipedia.org

Frequently asked questions